Harrow, Inc. Restricted Cash and Investments
Harrow, Inc. (HROW) had Restricted Cash and Investments of $6.71 million as of 2015-09-30, per its 10-Q filed 2015-11-12.
Discontinued › Balance Sheet › Assets › Restricted Cash and Investments
us-gaap:RestrictedCashAndInvestments · last filed 2015-11-12
- 2015-09-30: Restricted Cash and Investments $6.71M.
- 2015-06-30: Restricted Cash and Investments $10.20M.
- 2015-03-31: Restricted Cash and Investments $3.05M.
| Period end | Restricted Cash and Investments |
|---|---|
| 2015-09-30 | $6.71M 10-Q · filed 2015-11-12 |
| 2015-06-30 | $10.20M 10-Q · filed 2015-08-12 |
| 2015-03-31 | $3.05M 10-Q · filed 2015-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |